These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
383 related articles for article (PubMed ID: 17024483)
21. Gastrointestinal stromal tumors. Antonescu C Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552 [TBL] [Abstract][Full Text] [Related]
22. [Gastrointestinal stromal tumor of small intestine associated with lymph node metastasis: a report of 2 cases with review of literatures]. Kong M; Wang YL; Xu LJ; Teng XD Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):617-20. PubMed ID: 20079191 [TBL] [Abstract][Full Text] [Related]
23. Practical role of mutation analysis for imatinib treatment in patients with advanced gastrointestinal stromal tumors: a meta-analysis. Zhi X; Zhou X; Wang W; Xu Z PLoS One; 2013; 8(11):e79275. PubMed ID: 24223922 [TBL] [Abstract][Full Text] [Related]
24. Secondary resistance to imatinib mesylate in a patient with unresectable duodenal GIST without mutations in exons 9, 11, 13, or 17 of the c-kit protooncogene. Yamaguchi M; Matsumoto T; Tate G; Higuchi T J Gastroenterol; 2004 Sep; 39(9):904-5. PubMed ID: 15565413 [No Abstract] [Full Text] [Related]
25. Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients. Al-Batran SE; Hartmann JT; Heidel F; Stoehlmacher J; Wardelmann E; Dechow C; Düx M; Izbicki JR; Kraus T; Fischer T; Jäger E Gastric Cancer; 2007; 10(3):145-52. PubMed ID: 17922091 [TBL] [Abstract][Full Text] [Related]
26. [Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors]. Zhou Y; Hou YY; Tan YS; Lu SH; Hou J; Liu JL; Qin J; Shen KT; Sun YH Zhonghua Zhong Liu Za Zhi; 2009 Aug; 31(8):597-601. PubMed ID: 20021947 [TBL] [Abstract][Full Text] [Related]
28. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hornick JL; Fletcher CD Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861 [TBL] [Abstract][Full Text] [Related]
29. Effect of imatinib mesylate in a patient with a metastatic gastrointestinal stromal tumor with a c-kit mutation in exon 11. Kubota K; Katayama A; Takeshita Y; Nozaki K; Ueda T; Imamura K; Hiki N; Nomura S; Kaminishi M; Mafune K Dig Dis Sci; 2007 Jul; 52(7):1725-9. PubMed ID: 17546507 [No Abstract] [Full Text] [Related]
30. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation. Kang YK; Kang BW; Im SA; Lee JL; Park SR; Kang WK; Chang HM; Kim TW; Oh DY; Jung KH; Ryu MH Cancer Chemother Pharmacol; 2013 Jan; 71(1):43-51. PubMed ID: 23053257 [TBL] [Abstract][Full Text] [Related]
31. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor. Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK Oncology; 2009; 76(5):326-32. PubMed ID: 19307738 [TBL] [Abstract][Full Text] [Related]
33. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study. Kang HJ; Ryu MH; Kim KM; Park YS; Choi J; Ryoo BY; Kim WH; Im SA; Bang YJ; Park SH; Lee JH; Chung IJ; Bae HI; Kim JG; Lee KH; Song HS; Kwon HC; Baek JH; Shin DB; Lee KE; Kang YK Acta Oncol; 2012 Apr; 51(4):528-36. PubMed ID: 22150077 [TBL] [Abstract][Full Text] [Related]
35. Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations. Blay JY; Reichardt P Expert Rev Anticancer Ther; 2009 Jun; 9(6):831-8. PubMed ID: 19496720 [TBL] [Abstract][Full Text] [Related]
36. Efficacy evaluation of imatinib treatment in patients with gastrointestinal stromal tumors: a meta-analysis. Chen P; Zong L; Zhao W; Shi L World J Gastroenterol; 2010 Sep; 16(33):4227-32. PubMed ID: 20806443 [TBL] [Abstract][Full Text] [Related]
37. Advanced gastrointestinal stromal tumor patients with complete response after treatment with imatinib mesylate. Chiang KC; Chen TW; Yeh CN; Liu FY; Lee HL; Jan YY World J Gastroenterol; 2006 Apr; 12(13):2060-4. PubMed ID: 16610057 [TBL] [Abstract][Full Text] [Related]
38. Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors. Kikuchi H; Setoguchi T; Miyazaki S; Yamamoto M; Ohta M; Kamiya K; Sakaguchi T; Konno H Int J Clin Oncol; 2011 Dec; 16(6):741-5. PubMed ID: 21394667 [TBL] [Abstract][Full Text] [Related]
39. [Consensus on the medical treatment of gastrointestinal stromal tumors]. Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):875-7. PubMed ID: 18396652 [No Abstract] [Full Text] [Related]
40. [Clinical and molecular characterization of gastrointestinal stromal tumors (GIST)]. Mac K; Wójcik M Postepy Hig Med Dosw (Online); 2007 Jun; 62():272-81. PubMed ID: 18542042 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]